Optiscan Imaging (ASX:OIL) will conduct an imaging study in head and neck cancer surgery in collaboration with Australian Clinical Labs (ASX:ACL) using Optiscan's InVue precision surgery and InForm digital pathology devices, according to a Wednesday Australian bourse filing.

The study will use the devices to collect intra-operative surgical imaging data for patients undergoing surgery for oral, oropharyngeal, and associated squamous cell carcinomas of the head and neck region to evaluate real-time imaging in head and neck cancer surgery.

The study will also assess the uptake of the contrast agent fluorescein sodium and the dynamics of imaging normal and cancerous tissues, the filing said.

The study received ethical clearance from St John of God Health Care Research Ethics Committee, per the filing. It will recruit 50 patients undergoing head and neck cancer surgery as the standard of care.

The data generated from the study will support the US Food and Drug Administration regulatory submissions and advance Optiscan's oral cancer artificial intelligence imaging algorithm.

Australian Clinical Labs' shares fell past 1% in recent Wednesday trade.